P. Houghton, C. Morton, Chandra Tucker, D. Payne, Edward Favours, Claire Cole, R. Gorlick, E. Kolb, Wendong Zhang, R. Lock, H. Carol, M. Tajbakhsh, C. Reynolds, J. Maris, J. Courtright, S. Keir, H. Friedman, C. Stopford, J. Zeidner, Jianrong Wu, Tiebin Liu, C. Billups, J. Khan, S. Ansher, Jian Zhang, Malcolm A. Smith
2007.12.1PEDIATRIC BLOOD & CANCER
tlooto Summary
The characteristics of the in vivo tumor panels are described and results for the in vitro evaluation of two standard agents, vincristine and cyclophosphamide are reported.
Abstract
The Pediatric Preclinical Testing Program (PPTP) is an initiative supported by the National Cancer Institute (NCI) to identify novel therapeutic agents that may have significant activity against childhood cancers. The PPTP has established panels of childhood cancer xenografts and cell lines to be used for in vivo and in vitro testing. These include panels for Wilms tumor, sarcomas (rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma), neuroblastoma, brain tumors (glioblastoma, ependymoma, and medulloblastoma), rhabdoid tumors (CNS and renal), and acute lymphoblastic leukemia (ALL). Here, we describe the characteristics of the in vivo tumor panels and report results for the in vivo evaluation of two standard agents, vincristine and cyclophosphamide.
Citation format
HOUGHTON, P., et al. The pediatric preclinical testing program: Description of models and early testing results. PEDIATRIC BLOOD & CANCER, 2007, 49.